Targeted drug tested against Hard-to-Treat cancers with genetic flaw
NCT ID NCT04439201
Summary
This study is testing whether the drug palbociclib can shrink or stop the growth of advanced cancers that have specific genetic changes called CCND1, 2, or 3 amplification. The trial includes 40 patients with hard-to-treat solid tumors or lymphomas that have not responded to standard treatments. Researchers are giving patients palbociclib daily to see if blocking certain proteins can control these genetically-driven cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.